Navigation Links
Genomic Health Announces Oncotype DX(R) Provides Additional Prognostic Benefit in Patients Assessed With Adjuvant Online
Date:12/15/2007

udy found that the Recurrence Score result was a highly significant predictor of recurrence in both node-negative disease (p=0.0007) and node-positive disease (p=0.0004). In addition, a low Recurrence Score result predicted a low likelihood of recurrence regardless of nodal status.

"In examining the relationship between the Oncotype DX Recurrence Score and Adjuvant Online, we found that both tools have value in providing crucial information on the likelihood of breast cancer recurrence," said Peter Ravdin, M.D., Ph.D., the M.D. Anderson Cancer Center physician who developed the Adjuvant Online tool and a co-author of the study. "Specifically, the addition of Oncotype DX Recurrence Score results yielded supplementary insight on outcomes for breast cancer patients. Used together, we have the opportunity to more effectively guide personal treatment decisions based on a woman's individual breast cancer."

About Oncotype DX(R)

Oncotype DX is the first diagnostic multi-gene expression test commercially available that has clinical evidence validating its ability to predict the likelihood of breast cancer recurrence, the likelihood of breast cancer survival and the likelihood of chemotherapy benefit. Oncotype DX has been extensively evaluated in multiple independent studies involving more than 3,300 breast cancer patients, including a large validation study published in The New England Journal of Medicine and a chemotherapy benefit study published in the Journal of Clinical Oncology. To date, nearly 7,000 physicians have ordered more than 40,000 tests, and health plans covering over 50 percent of U.S. insured lives provide reimbursement for Oncotype DX through contracts, agreements and policy decisions. The American Society of Clinical Oncologists (ASCO) recommends the use of Oncotype DX for patients with node-negative breast cancer that is estrogen-receptor positive and/or progesterone-receptor positive. For more information about Oncotype DX, please vi
'/>"/>

SOURCE Genomic Health, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Anemia and tropical diseases; Is pharmacogenomics ready for the clinic?
2. Microarray provides 3 genomic guides to breast cancer treatment decisions
3. Genomic Health Announces Multiple Studies on Oncotype DX(TM) Presented at 2007 American Society of Clinical Oncology (ASCO) Breast Cancer Symposium
4. Genomic Health to Present at ThinkEquity Partners Fifth Annual Growth Conference
5. Genomic profiling of lung tumors helps doctors choose most effective treatment
6. Genomic technologies to identify toxic chemicals should be developed
7. Medco, LabCorp Strike Strategic Agreement for Research on Personalized Medicine and Pharmacogenomics
8. Genomic Health Reports Inclusion of Oncotype DX(TM) in American Society of Clinical Oncology Guidelines
9. Virginia Commonwealth University to Study Genomics-Based Diagnostic Test:
10. Millennium Announces MLN1202 Significantly Reduced Marker of Systemic Inflammation and Identifies Genomic Biomarker For Responders
11. Genomic Health to Present at JMP Securities Healthcare Focus Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... CA (PRWEB) April 17, 2015 The American College ... event and Free Application Day on April 29. The event will ... Pioneer Square, located at 555 DeHaro St. in San Francisco, CA. ... a.m. – Check in at the DeHaro campus (room F), 11:10 ... Tour of campus, Noon – Light lunch with current students, faculty ...
(Date:4/17/2015)... Compare-autoinsurance.org has released a new blog post explaining how ... . , The online environment can help many ... should always compare multiple car insurance policies before deciding ... competitive one, which means that customers can find new ... now possible to compare online car insurance quotes on ...
(Date:4/17/2015)... Lowcostcarinsuranceprice.com has released a new blog post explaining the ... car insurance rates . , Falling asleep at ... have a big impact on auto insurance prices. The premiums ... claimed benefits. The newly released blog post talks more about ... , It is now possible to find low cost ...
(Date:4/17/2015)... Ticket Down is a reputable source of authentic Mumford ... life of last-minute show announcements is where fans of Mumford and ... early part of 2015, but beginning in June, the group responsible ... Cave,” and “Believe,” will perform a full-fledged tour across North America. ... at Coney Island in Brooklyn, NY and ends on August 22 ...
(Date:4/17/2015)... April 17, 2015 Verndale, a Global ... has once again been chosen as a Boston Business ... private company in the region. The BBJ’s Pacesetters represents ... from 2011 through 2014. This is the eighth consecutive ... years that Verndale has been honored with this award. ...
Breaking Medicine News(10 mins):Health News:American College of Traditional Chinese Medicine Hosts Open House 2Health News:The Best Auto Insurance Quotes Are Available Online! 2Health News:Accidents Caused By Sleeping at The Wheel Can Increase Auto Insurance Costs 2Health News:Mumford and Sons Tickets in Clarkston/Detroit, Raleigh, Columbia/Baltimore, Chicago, Mansfield/Boston, Brooklyn, Calgary and Edmonton Now On Sale 2Health News:Verndale Honored as 2015 Boston Business Journal Pacesetter, Named 46th Fastest Growing Private Company 2
... , , , , , Quality Texas ... Award for Performance Excellence , ... Regional Medical Center at Grapevine is the 2009 recipient for the Texas Award for Performance ... Texas corporation that administers the Texas Award for Performance Excellence. , ...
... AMSTERDAM, June 17 , ... Among 100 Most,Influential Journals in Past Century , ... Publisher of the Last,100 Years in BioMedicine and the Life ... June 16th in Washington,DC. Twenty journals published by Elsevier, many ...
... NxStage Medical, Inc. (Nasdaq: NXTM ), a ... 5-year distribution agreement in the United States between its ... will supply blood tubing sets, including the ReadySet(R) and ... exclusively supply the bloodlines to certain customers for use ...
... Medco Health Solutions, and Blue Shield of California Look ... Calif., June 17 The State of California,s efforts ... received a shot in the arm today as The ... Blue Cross, Medco Health Solutions, Inc., and Blue Shield ...
... Collaboration will focus on the development of TMC207 and ... , SEATTLE, June 17 A new landmark ... (TB Alliance), a not-for-profit, product development partnership, and Tibotec ... today at the Pacific Health Summit in response to ...
... June 17 As job loss, bankruptcy, and divorce skyrocket ... hardships are struggling to cope. The burden of these concerns ... Joe Theu,s book "7 Proven Steps: How to Defeat Stress ... deal with the many different kinds of stress life can ...
Cached Medicine News:Health News:Tarrant County Hospital Takes Top Quality Award in Texas 2Health News:Tarrant County Hospital Takes Top Quality Award in Texas 3Health News:Elsevier Honored as "The Most Influential Publisher of the Last 100 Years in BioMedicine and the Life Sciences" by the Special Libraries Association 2Health News:Elsevier Honored as "The Most Influential Publisher of the Last 100 Years in BioMedicine and the Life Sciences" by the Special Libraries Association 3Health News:Elsevier Honored as "The Most Influential Publisher of the Last 100 Years in BioMedicine and the Life Sciences" by the Special Libraries Association 4Health News:NxStage(R) Announces Medisystems(R) Bloodline Distribution Agreement with Gambro 2Health News:NxStage(R) Announces Medisystems(R) Bloodline Distribution Agreement with Gambro 3Health News:California Doctors to Get Wired in State's Largest e-Prescribing Initiative 2Health News:California Doctors to Get Wired in State's Largest e-Prescribing Initiative 3Health News:California Doctors to Get Wired in State's Largest e-Prescribing Initiative 4Health News:California Doctors to Get Wired in State's Largest e-Prescribing Initiative 5Health News:California Doctors to Get Wired in State's Largest e-Prescribing Initiative 6Health News:California Doctors to Get Wired in State's Largest e-Prescribing Initiative 7Health News:Unique Collaboration Between TB Alliance and Tibotec To Accelerate Tuberculosis Drug Development 2Health News:Unique Collaboration Between TB Alliance and Tibotec To Accelerate Tuberculosis Drug Development 3Health News:Unique Collaboration Between TB Alliance and Tibotec To Accelerate Tuberculosis Drug Development 4Health News:Unique Collaboration Between TB Alliance and Tibotec To Accelerate Tuberculosis Drug Development 5Health News:Unique Collaboration Between TB Alliance and Tibotec To Accelerate Tuberculosis Drug Development 6Health News:'7 Proven Steps: How to Defeat Stress Without Going Through the Embarrassment of Counseling': Proven Ways to Defeat Stress 2Health News:'7 Proven Steps: How to Defeat Stress Without Going Through the Embarrassment of Counseling': Proven Ways to Defeat Stress 3
(Date:4/17/2015)... 17, 2015 Steven Rash , the CEO ... its operating subsidiary American Seed & Oil Company, presented ... investors yesterday in New York City.  Mr. Rash,s presentation ... American Seed & Oil Company has recently announced the ... Hemp Seed Foods , the EpiVape , and ...
(Date:4/17/2015)... and Markets ( http://www.researchandmarkets.com/research/256szd/corporate ) has announced ... in 2014 - a Perspective of Mental Health Patient ... For the first time, in 2014, the ... the pharmaceutical industry held by patient groups with an ... organisations representing all therapy areas. - Findings ...
(Date:4/16/2015)... April 16, 2015 Mindray Medical International ... and marketer of medical devices worldwide, announced today ... Exchange Commission an Annual Report on Form 20-F that ... 31, 2014. An electronic version of Mindray,s Annual ... investor relations website at  http://ir.mindray.com  or  http://www.sec.gov . ...
Breaking Medicine Technology:American Seed & Oil Company Benchmarks its Consumer Product Development Strategy Against Proctor & Gamble 2American Seed & Oil Company Benchmarks its Consumer Product Development Strategy Against Proctor & Gamble 3Corporate Reputation of Pharma in 2014 - The Perspective of Mental Health Patient Groups - 1st Edition 2Corporate Reputation of Pharma in 2014 - The Perspective of Mental Health Patient Groups - 1st Edition 3Mindray Files Annual Report on Form 20-F with the U.S. Securities and Exchange Commission 2
... May 22 Shire plc (LSE: SHP, Nasdaq: ... results of a study showing that coadministration of the ADHD ... (PPI) Prilosec OTC(R) 40 mg (20 mg X 2), did ... concentration of d -amphetamine to be reached in the ...
... Calif., May 21 Telik, Inc. (Nasdaq: TELK ... study of canfosfamide (TELCYTA(R), TLK286) in combination with pegylated liposomal ... annual meeting of the American Society of Clinical Oncology (ASCO) ... in Orlando, FL.Details of the presentation are as follows:, ...
Cached Medicine Technology:New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI) 2New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI) 3New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI) 4New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI) 5New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI) 6New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI) 7New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI) 8
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: